This dual therapy approach reduces PD-L1+ cells and promotes efficient tumor infiltration by effector CD8+ and CD4+ T cells, with increased IFN-γ, ICOS, granzyme B, and perforin expression. The gene discussed is CD8A; the disease is neoplasm.